Ancora Heart, Inc.
- Industry
- Medical Equipment Manufacturing
- Founded Year
- 0
- Headquarters
- Santa Clara, California
- Employee Count
- 0
Key People
- Jeff Closs - President and CEO
- Mark Miles - Chief Commercial Officer
- Ulrich P. Jorde, MD - Global Co-Principal Investigator of the CORCINCH-HF Study
- Mark Reisman, MD - Co-Principal Investigator of the CORCINCH-HF Study
Assessment
- Team
-
Aspect: First-time 10+ yrs
Summary: The leadership team comprises experienced professionals with significant tenure in the medical device industry.
The presence of seasoned executives and medical professionals in key roles suggests a strong foundation for strategic decision-making and operational execution.
- Clinical Need
-
Aspect: Very Strong
Summary: The AccuCinch System addresses a significant unmet need in heart failure treatment.
Heart failure with reduced ejection fraction (HFrEF) affects millions, and existing treatments are often insufficient. The AccuCinch System offers a novel, minimally invasive option that could improve patient outcomes.
- Competition
-
Aspect: First mover
Summary: The AccuCinch System is pioneering in its approach to ventricular restoration.
As the first completely transcatheter procedure targeting left ventricular enlargement, the AccuCinch System differentiates itself from existing therapies, potentially capturing significant market share.
- Technical Challenge
-
Aspect: Moderate
Summary: The development and implementation of the AccuCinch System involve moderate technical challenges.
The device's design and deployment require precision and innovation, but the company's experienced team is well-equipped to address these challenges.
- Patent
-
Aspect: Strong
Summary: The AccuCinch System is protected by strong patent coverage.
Strong patents safeguard the technology, preventing competitors from easily replicating the device and ensuring a period of market exclusivity.
- Financing
-
Aspect: Well-funded
Summary: Ancora Heart has secured substantial funding to support its operations and clinical trials.
The company's ability to attract significant investment reflects confidence in its technology and market potential, enabling sustained progress toward commercialization.
- Regulatory
-
Aspect: Pivotal Trial
Summary: The AccuCinch System is currently undergoing a pivotal clinical trial.
The CORCINCH-HF pivotal trial is designed to provide the necessary data for FDA approval. Achieving positive results is critical for the device's future market entry.
Opportunity Rollup
- Odds of Success
- 3.75
- Peak Market Share
- 5.1
- Segment CAGR
- 5.8%
- Market Segment
- Cardiovascular Devices
- Market Sub Segment
- Cardiac Assist Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.26 |
| 2 | 0.76 |
| 3 | 1.78 |
| 4 | 3.57 |
| 5 | 5.10 |
Key Takeaway
Ancora Heart's AccuCinch System addresses a significant unmet need in heart failure treatment, with strong leadership and promising clinical progress positioning it well for future success.